According to a new market research study titled "Neoantigens Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Treatment Modality, Cancer Indication, and Geography," the market is expected to grow from USD 271.43 million in 2023 to USD 1,054.78 million by 2028, at a CAGR of 31.2% during the forecast period.
Neoantigens—tumor-specific antigens arising from somatic mutations—are revolutionizing cancer immunotherapy by enabling highly personalized and precise therapeutic approaches. These unique antigens are recognized as “non-self” by the immune system, making them powerful targets for immunotherapy while minimizing damage to healthy tissues.
Key Market Drivers:
- Integration of AI & Machine Learning:
AI-powered platforms are being widely adopted to enhance neoantigen identification accuracy, accelerating drug development. For example, collaborations like NEC and Transgene’s use of AI for TG4050 highlight this trend. - Rise in Strategic Partnerships and Licensing:
Given the multidisciplinary nature of neoantigen development, companies are increasingly collaborating with CROs, academic institutions, and biopharma companies to co-develop products and expand global reach. - Adoption of Combination Therapies:
Neoantigen vaccines are frequently used in conjunction with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) to enhance T cell activation and tumor response. - Diversification Across Cancer Types:
While melanoma remains a key focus, developers are expanding pipelines to target gastrointestinal, lung, urinary system, and head & neck cancers. - Vertical Integration & Infrastructure Investment:
To accelerate development, many companies are investing in in-house sequencing, antigen synthesis, and bioinformatics platforms, allowing for faster turnaround and reduced cost.
Segmentation Overview:
- By Treatment Modality:
- Combination Therapy (largest market share in 2023)
- Monotherapy
- By Therapeutic Specialty:
- Gastrointestinal Cancer (largest share)
- Lung Cancer
- Solid Tumors
- Urinary System Cancers
- Melanoma
- Head & Neck Cancer
- Others
- By Geography:
- North America (market leader due to robust biotech infrastructure)
- Europe
- Asia-Pacific (expected to grow significantly due to regulatory modernization and R&D investments)
- Middle East & Africa
- South & Central America
Leading Market Players:
- Achilles Therapeutics plc
- Advaxis, Inc.
- Gritstone Oncology
- Genocea Biosciences
- BioNTech
- Moderna, Inc.
- Frame Cancer Therapeutics
- Gradalis, Inc.
- Immunicum AB
- Ziopharm Oncology, Inc.
- Medigene AG
These companies are advancing novel neoantigen platforms such as AI-driven prediction systems, ex vivo validation tools (e.g., ATLAS by Genocea), and personalized mRNA-based vaccines (e.g., Moderna’s mRNA-4157).
Market Challenges:
- High manufacturing complexity and cost
- Regulatory hurdles for personalized therapies
- Immunotoxicity risks and inconsistent clinical efficacy
- Competition from other immunotherapy modalities (e.g., CAR-T, TCR, bispecifics)
Strategic Insights:
- AI/ML integration will be a baseline requirement for future leaders.
- Modular and scalable neoantigen platforms will enable faster clinical transitions.
- Hybrid models (shared + personalized neoantigens) are emerging to balance cost and coverage.
- Asia-Pacific localization and real-world evidence generation will be critical to long-term market success.
Download Sample PDF Brochure Here:
https://www.theinsightpartners.com/sample/TIPRE00021781/
About Us:
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients gain insights into market dynamics, competitive landscape, technology trends, and future growth prospects. Our reports are designed to aid decision-makers in achieving sustainable growth in their respective domains.
For more information, please contact:
Email: [email protected]
Phone: +1-646-491-9876
Website: www.theinsightpartners.com
